Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

Uncovering Biomarker and Diagnostic Opportunities in Immune and Inflammatory Diseases

Published by: Decision Resources

Published: Aug. 21, 2009 - 28 Pages


Table of Contents


Executive Summary

Strategic Considerations

Stakeholder Implications

Introduction

Untapped Opportunity for Immune and Inflammatory Biomarkers

Diagnosing and Monitoring Immune and Inflammatory Diseases

Arthritic Conditions

Rheumatoid Arthritis

Juvenile Idiopathic Arthritis

Ankylosing Spondylitis

Systemic Lupus Erythematosus

Pulmonary and Respiratory Conditions

Asthma

Chronic Obstructive Pulmonary Disease

Inflammatory Bowel Disease

Crohn’s Disease

Ulcerative Colitis

Industry Trailblazers Advancing Biomarker Research and Product Development

Musculoskeletal Immune/Inflammatory Biomarker/Diagnostic Deals

General Immune/Inflammatory Biomarker/Diagnostic Deals

Respiratory Immune/Inflammatory Biomarker/Diagnostic Deals

Strategic Considerations

Major Breakthroughs Are Needed

Consider the Value of Initiatives to Increase Awareness and Physician Education

Ability to Predict Response to Therapy Would Be a Game Changer

Tables

1. Immune and Inflammatory Diseases Covered in This Report and Select Associated Biomarkers

2. Lupus Foundation of America’s Top Ten Advances for Systemic Lupus Erythematosus in 2008

3. Potential Biomarkers of Asthma and Chronic Obstructive Pulmonary Disease

4. Select Companies Focusing on Advancing Biomarker Opportunities in Immune and Inflammatory Diseases

Figures

1. Overall and Diagnosed Prevalence of Select Immune and Inflammatory Diseases in the United States, 2008

2. Pathological Changes in the Joints of Patients with Rheumatoid Arthritis

3. Rheumatologist-Estimated Percentage of Ankylosing Spondylitis Patients with Common Ankylosing Spondylitis Symptoms

4. Comorbidities Associated with COPD

5. Percentage of Immune/Inflammatory Biomarker/Diagnostic Deals by Deal Focus

6. Percentage of Immune/Inflammatory Biomarker/Diagnostic Deals by Therapeutic Area

7. Percentage of Companies Involved in Immune/Inflammatory Biomarker/Diagnostic Deals by Company Type

Abstract

Introduction

Despite the robust drug market for immune and infl ammatory diseases and their high prevalence, diagnostics associated with these diseases do not constitute a large marketplace. Although researchers are working to discover biomarkers, associate genes with disease, and develop diagnostics, a healthy commercial market for diagnostic technologies and biomarker-based products in immune and infl ammatory therapeutic areas is still years away. The present opportunity is to identify biomarkers with high levels of sensitivity and specificity that can be validated for use in drug or diagnostic development and, particularly, in disease management to guide and target the use of therapies.

Get the Answers You Need to Shape Your Strategy
  • Current ability to diagnose immune/infl ammatory diseases accurately and quickly is limited. What are the common diagnostic approaches? Which indications exhibit the highest level of unmet need in terms of diagnostics? How can diagnostics/biomarker developers tap the opportunities that current shortcomings present?
  • Biomarkers do not currently play a large role in clinical practice, but their potential utility is apparent. What do thought leaders say about biomarkers for immune/infl ammatory diseases? How can biomarkers target and track therapies? What developments of note are under way?
  • Large companies are interested in using biomarkers or diagnostics developed by smaller companies to target patients who are candidates for their immune/infl ammatory pipeline drugs. What proportion of the companies involved in these deals are private/venture-backed companies, small-cap companies, or academic institutions? How many of the 52 companies we analyze relied on backing from large-cap pharmaceutical companies?
Scope
  • Indications: systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), ankylosing spondylitis (AS), asthma, chronic obstructive pulmonary disease (COPD), and the infl ammatory bowel diseases (IBDs) Crohn's disease (CD) and ulcerative colitis (UC).
  • Diagnosis rates: diagnosed prevalence of select immune/infl ammatory diseases based on Decision Resources' epidemiology.
  • Current and future approaches: indication-specific modalities, challenges, opportunities, identified and posited biomarkers, published research results.
  • Dealmaking: Select deals for diagnostics and biomarkers, indication focus of dealmaking, classifications of dealmaking companies.
Please note, the PDF e-mail from publisher version of this report is for a global site license.

Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report

Price and Delivery Options
See related reports or call the number above for help from a research specialist.


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 300,000 market research reports, company profiles and country profiles from over 700 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2012
2/14/2012 - 32